in situ
As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense
TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment
Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding
Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding